Unlikely to cause harm — often a labeling or packaging issue.
CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose intermediates failed specifications.
| Brand name | AMLODIPINE BESYLATE |
| Generic name | AMLODIPINE BESYLATE |
| Active ingredient(s) | AMLODIPINE BESYLATE |
| Distributed by / for | Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 |
| NDC | 68180-752-03 |
| Full product label | Amlodipine Besylate Tablets USP, 10mg, 1000-count bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, Manufactured by: Lupin Limited Goa 403 722 INDIA, NDC 68180-752-03 |
| Recalling firm | Lupin Limited |
| Distribution | US No recalled product was distributed to any foreign consignees by Lupin. |
| Quantity | 11,812 bottles |
| Recall initiated | 2016-02-19 |
| Report date | 2016-09-14 |
| Recall completed | 2017-04-03 |
| Recall number | D-1493-2016 |
| Classification | Class III |
| FDA status | Terminated |
| Origin on file | Verna, Salcette, Goa India |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗